Results 191 to 200 of about 39,639 (239)
CD39+CD8+ T cell infiltration is associated with clinical outcomes of subsequent immunotherapy in advanced EGFR-mutant non-small cell lung cancer. [PDF]
Ther Adv Med OncolLu W +9 more
europepmc +1 more source
The Clinical Significance of CD73 in Cancer
International Journal of Molecular Sciences, 2023 The search for new and effective treatment targets for cancer immunotherapy is an ongoing challenge. Alongside the more established inhibitory immune checkpoints, a novel potential target is CD73. As one of the key enzymes in the purinergic signalling pathway CD73 is responsible for the generation of immune suppressive adenosine. The expression of CD73
Eva Tolosa +2 more
exaly +4 more sources
Cells, 2020 The ectonucleotidases CD39 and CD73 regulate immune responses by balancing extracellular ATP and adenosine in inflammation and are likely to be involved in the pathophysiology of COVID-19.
Friedrich Haag +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma
Biochimie, 2020The hypoxic environment of melanoma results in CD73 upregulation on the surface of various tumor microenvironment (TME) cells including tumor cells, stromal cells and infiltrated immune cells. Consequently, CD73 through both enzymatic and none enzymatic functions affect melanoma progression.
Amir Ghaderi +2 more
exaly +3 more sources
Targeting CD73 in the tumor microenvironment with MEDI9447 [PDF]
OncoImmunology, 2016 MEDI9447 is a human monoclonal antibody that is specific for the ectoenzyme CD73 and currently undergoing Phase I clinical trials. Here we show that MEDI9447 is a potent inhibitor of CD73 ectonucleotidase activity, with wide ranging immune regulatory consequences.
Melissa M. Damschroder +2 more
exaly +3 more sources
Cd73: An Emerging Checkpoint for Cancer Immunotherapy [PDF]
Immunotherapy, 2019 CD73 is a novel immune checkpoint associated with adenosine metabolism that promotes tumor progression by suppressing antitumor immune response and promoting angiogenesis. The inhibition of CD73, in combination with immune checkpoint blockade, targeted therapy or conventional therapy, improves antitumor effects in numerous preclinical mouse models of ...
Derek A. Wainwright, Yong Wan
exaly +3 more sources